Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

More Camden, N.J., Residents Using Needle Exchange Programs
A pilot needle exchange program in Camden, N.J., - one of four in the state - "was off to a slow start" when it began 18 months ago, but "now, 976 drug users have registered with the program - more people than those at the other pilot sites in Atlantic City, Newark or Paterson," the Cherry Hill Courier-Post reports. "In Camden, 854 people are living with HIV/AIDS, the eighth-highest number among New Jersey municipalities, according to the latest data from the state Department of Health and Senior Services. About a third of them were infected by dirty needles," the Courier-Post reports. Bob Baxter, who oversees Newark"s program, said needle exchanges provide "the most immediate benefit at the cheapest cost," in reducing the spread of blood-borne diseases. "While there"s no way to count the number of people who are no longer sharing needles because of the program, organizers say they hope to see their success correlate to lowered communicable disease rates," the article states (Hirsch, 7/20).
generic viagra online
Vetericyn Inc. Launches Equine Wound & Infection Product Utilizing FDA-Cleared Technology
Vetericyn Inc., a California-based animal healthcare company, has announced the launch of its new Vetericyn™ equine product, available in a 16-ounce trigger spray for horses. Vetericyn™ utilizes an FDA-cleared technology that has been used to successfully treat over one million human patients without a single serious adverse effect. Now, the innovative topical wound-care product is available to the animal healthcare market.
News of the day
St. Jude Medical Announces European Approval Of Accent RF And Anthem RF Pacemakers Equipped With Wireless Technology
St. Jude Medical, Inc. (NYSE:STJ) announced European CE Mark approval of its Accent™ RF pacemaker and Anthem™ RF CRT-P (cardiac resynchronization therapy pacemaker).
Diagnostics

Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties Of TAK-652 For The Treatment Of HIV

Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two Phase I pharmacokinetic studies for TAK-652, an investigational compound being developed for the treatment of HIV. These data suggest that TAK-652 is rapidly absorbed and demonstrate relatively good oral bioavailability (as shown by the plasma TBR-652 concentration data) and has a long plasma half-life of TBR-652 (approximate mean of 35 hours) supporting once-daily dosing. Mean TBR-652 plasma concentrations were well above the predicted target plasma concentration (2ng/mL) with or without food. In both studies TBR-652 was safe and well tolerated in this healthy subject population when administered over a dose range of 10 mg to 800 mg in 2 tablet formulations. "These two Phase I studies provide encouraging support for TAK-652 as a therapeutic option for the treatment of HIV. We look forward to results from our on-going proof-of-concept study," said James Sapirstein, CEO. About Tobira Therapeutics Inc. Tobira Therapeutics is a private biopharmaceutical company which is focused on developing and commercializing innovative antiviral compounds to treat HIV disease. The company was founded in 2006 by Eckard Weber, MD, a partner at the venture capital firm Domain Associates, to develop novel treatments for HIV disease. Tobira has assembled a highly experienced management team with decades of clinical and commercial development experience specifically in HIV/AIDS drug development. Tobira Therapeutics Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009